On Tuesday, Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s shares declined -6.81% to $13.42. s
Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, stated financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm stated that Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was presented during the quarter, counting single agent anti-tumor activity and durable disease control in patients with recurrent glioblastoma, advanced sarcomas, ovarian and endometrial cancers. They also presented survival data in patients with relapsed/refractory diffuse large B-cell lymphoma treated with selinexor, together with combination data of selinexor with chemotherapy in patients with heavily pretreated acute myeloid leukemia.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company’s lead drug candidate, Selinexor, a novel selective inhibitor of nuclear export (SINE) compounds that specifically blocks XPO1 cargo binding is in Phase II clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies.
Western Refining, Inc. (NYSE:WNR)’s shares dropped -0.57% to $49.03.
Western Refining, Inc. (WNR) stated results for its second quarter ending June 30, 2015. Net income attributable to Western, not taking into account special items, was $138 million, or $1.44 per diluted share. This compares to second quarter 2014 net income, not taking into account special items, of $128.8 million, or $1.29 per diluted share. Counting special items, the Company recorded second quarter 2015 net income attributable to Western of $133.9 million, or $1.40 per diluted share, as contrast to net income attributable to Western of $156.7 million, or $1.56 per diluted share for the second quarter of 2014.
Western paid a dividend of $0.34 per share of common stock to shareholders in the second quarter. In July, Western’s Board of Directors approved a $0.34 per share dividend for the third quarter. Counting the third quarter dividend, Western will have returned about $118 million to shareholders through dividends and share repurchases to date in 2015.
Western Refining, Inc. operates as an independent crude oil refiner and marketer of refined products. The company operates in four segments: Refining, NTI, WNRL, and Retail. The Refining segment owns and operates two refineries that process crude oil and other feed stocks primarily into gasoline, diesel fuel, jet fuel, and asphalt; and markets refined products to various customers, counting wholesale distributors and retail chains. The NTI segment owns and operates refining and transportation assets; and operates and supports retail convenience stores primarily in the Upper Great Plains region. As of December 31, 2014, this segment operated 165 retail convenience stores and supported 89 franchised retail convenience stores.
At the end of Tuesday’s trade, MannKind Corporation (NASDAQ:MNKD)‘s shares dipped -2.17% to $4.06.
MannKind Corporation (MNKD), a leading biopharmaceutical company focused on patient experience, acknowledged today that Executive Chairman Alfred Mann was honored last night at a gala for his extensive work in the progression and advancement of diabetes technologies and advocacy.
Held in conjunction with the 75th annual American Diabetes Association Scientific Sessions in Boston, the reception was co-hosted by Kelly L. Close, leading diabetes advocate and founder of the diaTribe Foundation, along with Dr. Steven Edelman, nationally recognized endocrinologist and founder of Take Control of Your Diabetes (TCOYD). In addition to last night’s honors, Mr. Mann was also recently awarded the JDRF’s Lifetime Achievement Award, one of the leading awards in diabetes internationally.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
Exelixis, Inc. (NASDAQ:EXEL), ended its Tuesday’s trading session with -5.45% loss, and closed at $5.72.
Exelixis, Inc. (EXEL) declared the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, counting deep expertise in global financial operations and controls, planned planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. He formerly spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company’s divisions and regions. He joins Exelixis in advance of several potentially transformational milestones anticipated this year, counting top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization.
In this role, Mr. Senner will oversee the company’s global finance function, leveraging extensive experience gained earlier in his career. While at Gilead, he was accountable for controllership and operational financial planning and analysis, counting research and development, manufacturing, commercial operations, and tax and treasury planning. At Wyeth, he served in a variety of capacities, most notably as CFO of the company’s $10 billion U.S. pharmaceuticals business and the BioPharma Business Unit, a $5 billion global inflammation, oncology and hematology business.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising about 45 clinical trials, counting 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
